CeQur announced that the Journal of Diabetes Science and Technology (JDST) has published a paper summarizing data from multiple studies evaluating whether the company’s PAQ basal-bolus insulin delivery device overcomes barriers to insulin delivery and meets the needs of people with type 2 diabetes and their healthcare providers. The data demonstrate that the simple three-day, wearable PAQ basal-bolus successfully addresses all key, known barriers, meets the needs of users, and is a safe and effective alternative to multiple daily insulin injections (MDI).
“CeQur set out to develop a device that would make it easier for people with type 2 diabetes to adhere to their insulin therapy and, thereby, have better clinical outcomes and quality of life,” said Julia Mader, M.D., of Medical University of Graz, Austria, and an author of the publication. “The collective data acquired from the company’s rigorous evaluation of the PAQ basal-bolus device demonstrates that they have achieved this goal.”
Two million people with type 2 diabetes in the United States take multiple daily insulin injections to control their blood glucose levels (HbA1c). Clinical practice guidelines published by the American Diabetes Association generally point to HbA1c levels below 7 percent (53 mmol/mol) as reasonable targets to help prevent diabetes complications. An estimated 70 percent of insulin users in the United States do not achieve this goal, primarily due to missed insulin injections.
Based on market research and human factor studies conducted among hundreds of people with diabetes and healthcare providers, CeQur designed the PAQ basal-bolus device to administer insulin in a way that is simple, discreet, safe and effective. The manuscript published in JDST summarizes data from extensive human factor testing (HFT), adhesive and clinical studies – all of which demonstrate that PAQ basal-bolus achieves these objectives, and ultimately helps people with type 2 diabetes improve their glycemic control.
Specifically, as compared to other modes of insulin delivery already available in the market, research demonstrated that the PAQ basal-bolus device is simpler and more discreet, while providing safe, effective insulin therapy.
“We systematically and strategically researched our key users’ requirements, and then very thoroughly evaluated the resulting insulin-delivery device to confirm that it fully and safely addresses these requirements,” said Robert Farra, CEO of CeQur. “The collective data demonstrate that the PAQ basal-bolus insulin-delivery device is an optimal alternative to multiple daily insulin injections.”